Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

NEW YORK, Aug. 13, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of SelectQuote, Inc. (NYSE: SLQT) between September 9, 2020 and May 1, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than October 10, 2025.So what: If you purchased SelectQuote securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or cos ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - Investors who suffered losses in RxSight between November 7, 2024, and July 8, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false or misleading statements regarding the company's sales and product demand [6]. - Specific allegations include that the company faced "adoption challenges" leading to declines in sales and utilization, overstated demand for its products, and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Group 3: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually heavy trading volume [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Petco Health and Wellness Company, Inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements about the sustainability of its business model and financial performance [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Petco to contact them to discuss their legal options [1]. - There is a deadline of August 29, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Petco [4]. - The investigation is focused on claims that Petco and its executives made false or misleading statements regarding the company's business model and financial health [6]. Group 2: Financial Performance - Petco reported net sales of $1.5 billion for the first quarter of 2025, which represents a 2.3% year-over-year decline [7]. - Following the release of these financial results, Petco's stock price fell by $0.85 per share, or 23.34%, closing at $2.78 per share on June 6, 2025 [7]. Group 3: Allegations of Misconduct - The complaint alleges that Petco's pandemic-related growth was unsustainable and that the company overstated its product strategy's effectiveness [6]. - It is claimed that the executives downplayed the severity of issues affecting the company and the necessary changes to address them, leading to an overestimation of Petco's ability to achieve sustainable growth [6].

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote, Inc. for allegedly misleading investors regarding its business practices and compliance with laws [1][2]. Allegations - The lawsuit claims that SelectQuote directed Medicare beneficiaries to insurers that compensated the company the most, regardless of the quality of the plans [2]. - It is alleged that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [2]. - The company is accused of violating applicable laws and regulations, making it vulnerable to regulatory and legal sanctions, including claims under the False Claims Act [2][3]. Legal Developments - On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to at least 2021 [3]. - The DOJ's complaint states that SelectQuote made materially false claims about offering unbiased coverage comparisons while actually directing beneficiaries to the most profitable plans [3]. Market Reaction - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Background - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. - The misleading statements resulted in investors suffering damages when the true details about Replimune's business and operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of false and misleading statements regarding the company's performance and financial guidance, particularly following a significant drop in stock price after disappointing financial results [2][4][5]. Group 1: Company Performance and Allegations - The complaint against RxSight alleges that the company and its executives violated federal securities laws by failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [4]. - RxSight overstated the demand for its products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full year 2025 guidance by approximately $42.5 million at the midpoint [5]. Group 2: Stock Market Reaction - On July 9, 2025, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share, following the announcement of disappointing financial results and guidance [5]. Group 3: Legal Proceedings - Investors who purchased or acquired securities in RxSight between November 7, 2024, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of September 22, 2025, to seek the role of lead plaintiff in a federal securities class action [2][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought Flywire securities between February 28, 2024, and February 25, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 23, 2025 [3]. - The lawsuit alleges that Flywire's management made false and misleading statements regarding the sustainability of revenue growth and the impact of permit and visa-related restrictions on the business [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Vestis Corporation during the specified class period of the upcoming lead plaintiff deadline on August 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Vestis Corporation, and investors who wish to serve as lead plaintiffs must act by August 8, 2025 [2]. - The lawsuit alleges that Vestis provided misleading statements about its business growth and strategic initiatives, which ultimately led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...